Clinical trials: RAS Wild Type
Metastatic Colo-rectal Cancer
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS…
- Trial name
- TRIP (NCT01358812)
- Testing
- FOLFOXIRI + Panitumumab
- Where
- 10 sites in Italy
- Volunteers
- 37 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Antineoplastic Agents
Erbitux MEtastatic Colorectal Cancer Strategy Study
To investigate whether cetuximab alone (given until progression or cumulative toxicity) after 8 cycles of FOLFIRI + cetuximab results in a non inferior Progression Free Survival when compared with continuous FOLFIRI + cetuximab…
- Trial name
- NCT02484833
- Testing
- Cetuximab, FOLFIRI
- Where
- Italy
- Volunteers
- 607 people
- Sponsor
- Armando Orlandi
Colorectal Adenocarcinoma, RAS Wild Type
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally…
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02292758
- Testing
- Bevacizumab, Cetuximab, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer Metastatic
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.
- Trial name
- STRATEGIC-1 (NCT01910610)
- Testing
- FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab
- Where
- 56 sites in France, Ireland and 1 more
- Volunteers
- 464 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer, RAS Wild-type
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)
A safety and efficacy study of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting…
- Trial name
- VALIDATE (NCT03043950)
- Testing
- Panitumumab
- Where
- Germany
- Volunteers
- 647 people
- Sponsor
- iOMEDICO AG